Gemzar Ovarian Cancer Data Not Sufficient For Approval In Recurrent Disease, Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
While FDA advisory committee accepts that Lilly’s Gemzar plus carboplatin may have had an effect on progression-free survival in ovarian cancer, poor study design and lack of overall survival benefit sink approval recommendation.